



OMIDRIA®

(phenylephrine and ketorolac
intraocular solution)
1% / 0.3%

Billing and Reimbursement Guide

- Codes and guidance on completing claim forms for Medicare Fee-for-Service, Medicare Advantage, and commercial payers
- Billing and reimbursement information for OMIDRIA
- Details on ordering OMIDRIA
- Helpful resources

About OMIDRIA® (phenylephrine and ketorolac intraocular solution) 1%/0.3%

OMIDRIA is the first and only FDA-approved drug that provides continuous intracameral delivery of an NSAID and a mydriatic agent during cataract surgery.¹

OMIDRIA is a non-opioid medication added to the irrigating solution used during cataract surgery and lens replacement¹

Provides direct and continuous intracameral delivery of an NSAID and a mydriatic agent, delivered at the site of care.¹

Optimize time. Maximize control. Go dropless with OMIDRIA.

- **Streamlines** cataract surgery
- **Effectively maintains pupil dilation** and requires less use of PEDs¹⁻⁸
- **Reduces complications** such as IFIS, CME, and breakthrough iritis⁷
- **Improved patient experience** with less pain, greater visual acuity, and fewer to no drops^{1,2,9,10}
- **Places control** and **surgical outcomes** in surgeon's hands
- **Minimizes the risks and liabilities** of compounded products



CME=Cystoid Macular Edema; IFIS=Intraoperative Floppy Iris Syndrome;
NSAID=Nonsteroidal Anti-inflammatory Drug; PED=Pupil Expansion Device.

Please see Important Safety Information on page 11
and Full Prescribing Information at omidria.com



OMIDRIA®
(phenylephrine and ketorolac
intraocular solution)
1% / 0.3%

Coding for OMIDRIA*

OMIDRIA has a unique permanent J-code†

J1097

^{11, 12}

phenylephrine 10.16 mg/mL and ketorolac 2.88 mg/mL
ophthalmic irrigation solution, 1 mL

1 billing unit = 1 mL; one standard 4-mL vial = 4 units.

Sample CPT® codes¹³

66984 Uncomplicated cataract surgery

66982[‡] Complex cataract surgery

66983, 66989, 66991, 66988 Related intraocular lens procedures

CPT modifier¹⁴

RT/LT

Right eye/Left eye

HCPCS and NDC codes for OMIDRIA

HCPCS code ^{11, 12}	APC	HCPCS modifier ¹⁵	Long descriptor ¹²	NDC number ¹
J1097	9324	JZ** TB***	Phenylephrine 10.16 mg/mL and ketorolac 2.88 mg/mL ophthalmic irrigation solution, 1 mL	82604-0600-04 (11-digit)

Important reminders

- The OMIDRIAssure program provides assistance for financially eligible uninsured or underinsured patients and those with insufficient commercial insurance†
- Questions related to a patient's eligibility for OMIDRIAssure should be addressed by calling the Live Assistance Reimbursement Hotline at 1-877-OMIDRIA (1-877-664-3742), contacting your OMIDRIA Field Reimbursement Manager, or working directly with your payer provider representative
- Coverage and payment may vary by payer, contractual agreements, and site of service

INDICATIONS AND USAGE

OMIDRIA® (phenylephrine and ketorolac intraocular solution) 1% / 0.3% is added to ophthalmic irrigating solution used during cataract surgery or intraocular lens replacement and is indicated for maintaining pupil size by preventing intraoperative miosis and reducing postoperative ocular pain.

IMPORTANT SAFETY INFORMATION

The most commonly reported adverse reactions at ≥ 2% are eye irritation, posterior capsule opacification, increased intraocular pressure, and anterior chamber inflammation.

You are encouraged to report Suspected Adverse Reactions to the FDA.

Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

CPT is a registered trademark of the American Medical Association.

*Individual plan coverage, payment, policies, and procedures vary and should be confirmed by the facility. Rayner does not guarantee reimbursement.

†Information contained in this guide is provided as a reference for obtaining appropriate and accurate reimbursement for the use of OMIDRIA in eligible patients. Rayner does not guarantee reimbursement. OMIDRIAssure program services are subject to change without notice.

‡If surgery is for complex cataract surgery, physician should note the ICD-10-CM code or reason why the surgery is complex.

CPT=Current Procedural Terminology; HCPCS=Healthcare Common Procedure Coding System;

ICD-10-CM=International Classification of Diseases, Tenth Revision, Clinical Modification;

NDC=National Drug Code, APC=Ambulatory Payment Classification.

** Used in ASC and HOPD

*** Used in 340b Hospitals

Please see Important Safety Information on page 11
and Full Prescribing Information at omidria.com



OMIDRIA®

(phenylephrine and ketorolac
intraocular solution)
1% / 0.3%

Resources

(phenylephrine and ketorolac
intraocular solution)
1% / 0.3%

Sample UB-04 (CMS-1450) Paper Claim Form¹⁷

Form Locator 4:

Enter 4-digit code that specifies place of service and submission type. For example, for HOPD, the first 3 digits are 013. The final digit is usually a "1," meaning one claim for the event

Enter all applicable patient information

Form Locator 17:

Enter Patient Status

Form Locator 47:

Enter charges for OMIDRIA

Form Locator 42*:

Enter Revenue Code

Form Locator 43:

Enter N4 qualifier and 11-digit NDC number and UNI

Form Locator 44:

Enter unique Billing Code for OMIDRIA and modifier (JZ) *Note 340b add TB modifier.

Form Locator 44:

Enter Procedure Code(s)

Form Locator 46:

Enter 4 units

Form Locator 50A:

If Medicare is the primary payer, enter "Medicare" on line A

Form Locator 67:

Enter primary Diagnosis Code

Form Locator 66:

Enter "O" if using ICD-10-CM

Form Locator 80:


Used to display remarks or additional information that may be needed to process a claim

1 Any Hospital 123 Any Street Philadelphia, PA 19103		2 Any Hospital 123 Any Street Philadelphia, PA 19103		3a PAT. CNTL. # b. MED. REC. # 1234 98765	4 TYPE OF BILL 0131
8 PATIENT NAME Doe, John		9 PATIENT ADDRESS 1234 Main Street Philadelphia		10 STATE PA	
11 SEX M		12 DATE 03 20 1971		13 ADMISSION 14 TYPE 15 SRC 16 DHR 17 STAT 18 19 20 21	
31 OCCURRENCE DATE 03 20 1971		32 OCCURRENCE DATE M		33 OCCURRENCE DATE 01	
34 OCCURRENCE DATE 01		35 OCCURRENCE DATE 01		36 OCCURRENCE DATE 01	
37 OCCURRENCE DATE 01		38 OCCURRENCE DATE 01		39 OCCURRENCE DATE 01	
39 CODE a		40 CODE b		41 CODE c	
42 REV. CODE 272		43 DESCRIPTION N482604060004 UN1		44 HCPCS / RATE / HPPS CODE J1097 JZ	
276		276		276	
300		300		300	
360		360		360	
370		370		370	
710		710		710	
45 SERV. DATE		46 SERV. UNITS 4		47 TOTAL CHARGES	
48 NON-COVERED CHARGES		49		50	
51 HEALTH PLAN ID		52 PRIOR PAYMENTS		53 EST. AMOUNT DUE	
54		55		56 NPI 222222222	
57		58		59	
60		61		62	
63		64		65	
66		67		68	
69		70		71	
72		73		74	
75		76		77	
78		79		80	
81		82		83	
84		85		86	
87		88		89	
90		91		92	
93		94		95	
96		97		98	
99		100		101	
102		103		104	
105		106		107	
108		109		110	
111		112		113	
114		115		116	
117		118		119	
120		121		122	
123		124		125	
126		127		128	
129		130		131	
132		133		134	
135		136		137	
138		139		140	
141		142		143	
144		145		146	
147		148		149	
150		151		152	
153		154		155	
156		157		158	
159		160		161	
162		163		164	
165		166		167	
168		169		170	
171		172		173	
174		175		176	
177		178		179	
180		181		182	
183		184		185	
186		187		188	
189		190		191	
192		193		194	
195		196		197	
198		199		200	
201		202		203	
204		205		206	
207		208		209	
210		211		212	
213		214		215	
216		217		218	
219		220		221	
222		223		224	
225		226		227	
228		229		230	
231		232		233	
234		235		236	
237		238		239	
240		241		242	
243		244		245	
246		247		248	
249		250		251	
252		253		254	
255		256		257	
258		259		260	
261		262		263	
264		265		266	
267		268		269	
270		271		272	
273		274		275	
276		277		278	
279		280		281	
282		283		284	
285		286		287	
288		289		290	
291		292		293	
294		295		296	
297		298		299	
300		301		302	
303		304		305	
306		307		308	
309		310		311	
312		313		314	
315		316		317	
318		319		320	
321		322		323	
324		325		326	
327		328		329	
330		331		332	
333		334		335	
336		337		338	
339		340		341	
342		343		344	
345		346		347	
348		349		350	
351		352		353	
354		355		356	
357		358		359	
360		361		362	
363		364		365	
366		367		368	
369		370		371	
372		373		374	
375		376		377	
378		379		380	
381		382		383	
384		385		386	
387		388		389	
390		391		392	
393		394		395	
396		397		398	
399		400		401	
402		403		404	
405		406		407	
408		409		410	
411		412		413	
414		415		416	
417		418		419	
420		421		422	
423		424		425	
426		427		428	
429		430		431	
432		433		434	
435		436		437	
438		439		440	
441		442		443	
444		445		446	
447		448		449	
450		451		452	
453		454		455	
456		457		458	
459		460		461	
462		463		464	
465		466		467	
468		469		470	
471		472		473	
474		475		476	
477		478		479	
480		481		482	
483		484		485	
486		487		488	
489		490		491	
492		493		494	
495		496		497	
498		499		500	
501		502		503	
504		505		506	
507		508		509	
510		511		512	
513		514		515	
516		517		518	
519		520		521	
522		523		524	
525		526		527	
528		529		530	
531		532		533	
534		535		536	
537		538		539	
540		541		542	
543		544		545	
546		547		548	
549		550		551	
552		553		554	
555		556		557	
558		559		560	
561		562		563	
564		565		566	
567		568		569	
570		571		572	
573		574		575	
576		577		578	
579		580		581	
582		583		584	
585		586		587	
588		589		590	
591		592		593	
594		595		596	
597		598		599	
600		601		602	
603		604		605	
606		607		608	
609		610		611	
612		613		614	
615		616		617	
618		619		620	
621		622		623	
624		625		626	
627		628		629	
630		631		632	
633		634		635	
636		637		638	
639		640		641	
642		643		644	
645		646		647	
648		649		650	
651		652		653	
654		655		656	
657		658		659	
660		661		662	
663		664		665	
666		667		668	
669		670		671	
672		673		674	
675		676		677	
678		679		680	
681		682		683	
684		685		686	
687		688		689	
690		691		692	
693		694		695	
696		697		698	
699		700		701	
702		703		704	
705		706		707	
708		709		710	
711		712		713	
714		715		716	
717		718		719	
720		721		722	
723		724		725	
726		727		728	
729		730		731	
732		733		734	
735		736		737	
738		739		740	
741		742		743	
744		745		746	
747		748		749	
750		751		752	
753		754		755	
756		757		758	
759		760		761	
762					

Understanding Billable Status for Patients Receiving OMIDRIA

Patient insurance benefits are typically comprised of primary and additional coverage that determine billable status

Work with your OMIDRIA Field Reimbursement Manager to determine billable status for your payers*



*Individual plan coverage, payment, policies, and procedures vary and should be confirmed by the facility. Rayner does not guarantee reimbursement.

†Patients with Medicare Part B will not be eligible for company programs.

DOD=Department of Defense; FFS=Fee-for-Service.

Please see Important Safety Information on page 11 and Full Prescribing Information at [omidria.com](https://www.omidria.com)



OMIDRIA®

(phenylephrine and ketorolac
intraocular solution)
1% / 0.3%

Medicare Fee-for-Service Billing and Reimbursement

HCPCS and NDC codes for OMIDRIA

HCPCS code ^{11, 12}	APC	HCPCS modifier ¹⁵	Long descriptor ¹²	NDC number ¹
J1097	9324	JZ* TB**	Phenylephrine 10.16 mg/mL and ketorolac 2.88 mg/mL ophthalmic irrigation solution, 1 mL	82604-0600-04 (11-digit)

Reimbursed with separate payment

OMIDRIA has separate payment status in ASCs and HOPDs for 100% of fee-for service Medicare patients***

For OMIDRIA reimbursement in the **ASC** setting, CMS reimburses **80%** of current Medicare Fee schedule.

For OMIDRIA in the **HOPD** setting, CMS reimburses **100%** of the current Medicare fee schedule.

OMIDRIAssure
SUPPORT AT EVERY STEP

The OMIDRIAssure program offers patients options to assist with the cost of OMIDRIA:



We Pay the Difference patient reimbursement program for commercially insured patients.†



Equal Access patient assistance program for financially eligible uninsured or underinsured patients.



Field Reimbursement Managers are highly experienced in helping you navigate through the reimbursement pathway.

For personalized help, call the Live Assistance Reimbursement Hotline at 1-877-OMIDRIA (1-877-664-3742), 8 AM-8 PM ET, Monday-Friday‡

* Used in ASC and HOPD

** Used in 340b Hospitals

*** OMIDRIA qualifies for separate payment across both ASC and HOPD settings as it fulfills the requirements established in the non-opioid as a surgical supply provision by CMS.

† Based on your Medicare or commercial plan selection, your coverage may require a copay for OMIDRIA.

‡ Benefit verifications may not address contracted payer payment rates.

APC=Ambulatory Payment Classifications; ASC=Ambulatory Surgery Center; HCPCS=Healthcare Common Procedure Coding System; HOPD=Hospital Outpatient Department; NDC=National Drug Code.

Many medications require coinsurance. Healthcare providers are contractually obligated to collect applicable patient responsibility. Failure to adhere to regulations may lead to legal issues under the False Claims Act and Anti-Kickback Statute or result in audits and reimbursement penalties from insurers, including exclusion from federal healthcare programs. CMS Fraud Waste and Abuse disallows regular waiver of coinsurance.

Please see Important Safety Information on page 11 and Full Prescribing Information at omidria.com



OMIDRIA

(phenylephrine and ketorolac
intraocular solution)
1% / 0.3%

Medicare Advantage Billing and Reimbursement

- In the Contract Year 2024 MA and Part D final rule published April 2023, CMS updated rules for Medicare Advantage (Part C) plans to make clear what they must cover and how they decide on what is necessary care. CMS regulations at §422.101(a) and (b) require that MA plans provide coverage of all basic benefits (that is, services covered under Medicare Parts A and B) and that MA plans must comply with Traditional Medicare national coverage determinations (NCDs) and local coverage determinations (LCDs) applicable in the MA plan's service area.¹⁸
- In 2024, 54% of Medicare beneficiaries were enrolled in MA plans, with projections indicating an increase to 64% by 2033.¹⁹

May or may not use Medicare FFS payment rate as a benchmark

- Like traditional Medicare FFS, Medicare Advantage plans should cover OMIDRIA, but the payment rate may differ from traditional FFS or be subject to payer-specific facility contractual limitations*
- For a Medicare Advantage patient, the specific Medicare Advantage payer should be contacted in advance to determine its reimbursement process as well as the level of reimbursement for OMIDRIA

Best practices for dealing with Medicare Advantage plans

- Before surgery, verify if patient has a Medicare Advantage plan
- Check if your facility-specific payer contracts follow Medicare guidelines or allow for separate payment of drugs and biological (carve outs)
- If the plan bundles payment for OMIDRIA, share the CMS announcement regarding separate billable status

You can look up a patient's Medicare plan by entering the patient's name and date of birth in any of the following databases, among others:

- Secure Provider Online Tool (SPOT), provided by First Coast MAC
- Availity (for BCBS, Aetna, Humana)
- Palmetto e-services
- Noridian Medicare Portal

You do not need to pay a subscription fee to access these databases



EQUAL ACCESS

PATIENT ASSISTANCE PROGRAM

Assistance for financially eligible uninsured or underinsured patients

For patients who meet certain financial criteria, Rayner has established the Equal Access Patient Assistance Program as part of OMIDRIAssure.†

- Eligible patients will receive OMIDRIA at no cost
- Free vial will be sent to your facility prior to surgery
- Application for free vial must be completed and approved at least 5 days prior to date of surgery

* Rayner does not guarantee payment by any payer.

† To be eligible for the Equal Access Patient Assistance Program, patients must be enrolled prior to surgery. Program is subject to change without notice. For any patient eligible for the Equal Access Patient Assistance Program, (1) the facility receives a free vial of OMIDRIA prior to surgery, and (2) the patient's insurance carrier(s) should not be billed for OMIDRIA.

BCBS=Blue Cross Blue Shield; CMS=Centers for Medicare & Medicaid Services; FFS=Fee-for-Service; MA=Medicare Advantage.

Please see Important Safety Information on page 11 and Full Prescribing Information at [omidria.com](https://www.omidria.com)



OMIDRIA®

(phenylephrine and ketorolac
intraocular solution)
1% / 0.3%

Commercial Insurance Billing and Reimbursement

May reimburse with bundled payment

- Of all insurance types, commercial payers are the most likely to bundle payment for OMIDRIA with that for the cataract surgery procedure

Payment rate will vary by plan

- The amount commercial payers will reimburse for use of OMIDRIA may be dependent on the terms in the contract with the payer
- Work with your OMIDRIA Field Reimbursement Manager to determine billable status for your payers*

Identify the Payer Methodology

- How is the payment rate structured across the various payers?*
- For a commercial patient, the specific payer should be contacted in advance to determine its reimbursement process as well as the level of reimbursement for OMIDRIA

Best practices for commercial payers

- Check if your facility-specific payer contracts allow for separate payment of drugs and biologics (carve out)
- Verify payer-specific use of appropriate revenue code
- Cultivate relationship with payer-provider network representative



WE PAY THE DIFFERENCE PATIENT REIMBURSEMENT PROGRAM

Assistance for patients with insufficient commercial insurance

- Rayner will pay your facility, on behalf of your patient, the difference between your facility's acquisition cost for OMIDRIA and the amount covered by your commercially insured patient's insurance†
- Visit <https://www.omidria.com/access-and-support> to download the We Pay the Difference Enrollment Form, We Pay the Difference Instruction Form, and other available resources

Reach out to our FRM team for additional support by emailing
omidriafrms@rayner.com or by calling 1-844-RAYNER1 (1-844-729-6371)

* Individual plan coverage, payment, policies, and procedures vary and should be confirmed by the facility. Rayner does not guarantee reimbursement.

† OMIDRIAssure program services are subject to change without notice. The We Pay the Difference Patient Reimbursement Program patient benefit is not available for patients with any government insurance. Rayner does not guarantee reimbursement. Facility acquisition cost is determined after application of any volume-based discount. Claims must be submitted within 90 days of date of surgery. Rayner does not guarantee coverage or reimbursement.



OMIDRIA®

(phenylephrine and ketorolac
intraocular solution)
1% / 0.3%

Ordering OMIDRIA for Your Facility

How to order OMIDRIA

OMIDRIA is supplied in a clear, 5-mL glass, single-patient-use vial containing 4 mL of sterile solution. The smallest sellable unit is a carton, which contains four (4) single-patient-use vials.

NDC#: 82604-600-04

*Use the 10-digit NDC for ordering and the 11-digit NDC for billing.

One (1) carton is the minimum order. OMIDRIA is sold only in carton quantities. OMIDRIA is not sold in individual vial quantities.



x1



x4

One (1) carton contains four (4) single-patient-use vials*



x30



x120

One (1) case contains thirty (30) cartons (120 total vials)

OMIDRIA is available through specialty distributors

McKesson Specialty Distribution[†]

Item number: 5016421 Contact number: 1-800-482-6700

McKesson Plasma and Biologics[†]

Item number: 2856201 Contact number: 1-877-625-2566

Cardinal Health Specialty Distribution[‡]

Item number: 5875778 Contact number: 1-855-855-0708

Besse Medical

Item number: 10283186 Contact number: 1-888-767-7123

AmerisourceBergen Specialty Distribution[§]

Item number: 10283069 Contact number: 1-800-746-6273

FFF Enterprises, Inc. (Offering consignment services)

Item number: OMI4060004 Contact number: 1-800-843-7477

McKesson Medical-Surgical

Item number: 1278880 Contact number: 1-855-571-2100

[†] For customers of McKesson full-line wholesaler division, OMIDRIA is available for purchase through McKesson Plasma and Biologics and McKesson Specialty Distribution.

[‡] For customers of Cardinal full-line wholesaler division, OMIDRIA is available for purchase through Cardinal Health Specialty Distribution.

[§] For customers of AmerisourceBergen Corporation full-line wholesale division, OMIDRIA is available through AmerisourceBergen specialty distribution and can be ordered using the Passport ordering platform through AmerisourceBergen.

NDC=National Drug Code.

Please see Important Safety Information on page 11 and Full Prescribing Information at [omidria.com](https://www.omidria.com)



OMIDRIA[®]

(phenylephrine and ketorolac
intraocular solution)
1% / 0.3%

HELPFUL RESOURCES*

www.cms.gov

- ASC (Addendum BB) and HOPD (Addendum A) Payment Rates and Updates
- CMS ASP Drug Pricing Files
- CMS Quarterly Update
- MLN Matters Articles

<https://www.omidria.com/access-and-support>

- We Pay the Difference Instruction Form
- We Pay the Difference Enrollment Form
- OMIDRIAssure Patient Certification Form
- Billing and Reimbursement Guide

*Rayner does not guarantee the accuracy, completeness, or current status of information provided on third-party websites.

ASC=Ambulatory Surgery Center; ASP=average sales price; CMS=Centers for Medicare & Medicaid Services; HOPD=hospital outpatient department; MLN=Medicare Learning Network®.

INDICATIONS AND USAGE

OMIDRIA® is added to ophthalmic irrigating solution used during cataract surgery or intraocular lens replacement and is indicated for maintaining pupil size by preventing intraoperative miosis and reducing postoperative ocular pain.

IMPORTANT SAFETY INFORMATION

OMIDRIA must be added to irrigating solution prior to intraocular use.

OMIDRIA is contraindicated in patients with a known hypersensitivity to any of its ingredients.

Systemic exposure of phenylephrine may cause elevations in blood pressure.

Use OMIDRIA with caution in individuals who have previously exhibited sensitivities to acetylsalicylic acid, phenylacetic acid derivatives, and other nonsteroidal anti-inflammatory drugs (NSAIDs), or have a past medical history of asthma.

The most commonly reported adverse reactions at $\geq 2\%$ are eye irritation, posterior capsule opacification, increased intraocular pressure, and anterior chamber inflammation.

Please see the [Full Prescribing Information](#) for OMIDRIA.

You are encouraged to report Suspected Adverse Reactions to the FDA.

Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

References: 1. OMIDRIA [package insert]. Bellevue, WA: Rayner Surgical Inc. 2023. 2. Rosenberg ED, Nattis AS, Alevi D, et al. Visual outcomes, efficacy, and surgical complications associated with intracameral phenylephrine 1.0%/ketorolac 0.3% administered during cataract surgery. *Clin Ophthalmol*. 2018;12:21-28. 3. Al-Hashimi S, Donaldson K, Davidson R, et al. Medical and surgical management of the small pupil during cataract surgery. *J Cataract Refract Surg*. 2018;44:1032-1041. 4. Bucci FA Jr, Michalek B, Fluet AT. Comparison of the frequency of use of a pupil expansion device with and without an intracameral phenylephrine and ketorolac injection 1%/0.3% at the time of routine cataract surgery. *Clin Ophthalmol*. 2017;11:1039-1043. 5. Matossian C. Clinical and economic outcomes in cataract surgery using phenylephrine 1.0%-Ketorolac 0.3% in a real-world setting. Abstract presented at: Annual Meeting of the American Society of Cataract and Refractive Surgeons (ASCRS); April 16, 2018; Washington, DC. Course 5219. 6. Walter K, Delwadia N, Coben J. Continuous intracameral phenylephrine-ketorolac irrigation for miosis prevention in femtosecond laser-assisted cataract surgery: reduction in surgical time and iris manipulation. *J Cataract Refract Surg*. 2019;45(4):465-469. 7. Visco D. Effect of phenylephrine/ketorolac on iris fixation ring use and surgical times in patients at risk of intraoperative miosis. *Clin Ophthalmol*. 2018;12:301-305. 8. Silverstein SM, Rana VK, Stephens R, et al. Effect of phenylephrine 1.0%-ketorolac 0.3% injection on tamsulosin-associated intraoperative floppy-iris syndrome. *J Cataract Refract Surg*. 2018;44(9):1103-1108. 9. Visco DM, Bedi R. Effect of intracameral phenylephrine 1.0%-ketorolac 0.3% on postoperative cystoid macular edema, iritis, pain, and photophobia after cataract surgery. *J Cataract Refract Surg*. 2020;46(6):867-872. 10. Donnenfeld ED, Hovanesian JA, Malik AG, Wong A. A randomized, prospective, observer-masked study comparing dropless treatment regimen using intracanalicular dexamethasone insert, intracameral ketorolac, and intracameral moxifloxacin versus conventional topical therapy to control postoperative pain and inflammation in cataract surgery. *Clin Ophthalmol*. 2023;17:2349-2356. 11. American Medical Association. HCPCS code for global fee urgent care centers J1097. Accessed September 23, 2025. <https://hcpcs.codes/j-codes/J1097/> 12. Billing and Coding: Cataract Extraction (including Complex Cataract Surgery) A58592, Medicare Coverage Database CMS.gov; Billing and Coding: Use of Laterality Modifiers A56860, Medicare Coverage Database CMS.gov 13. Jagmin CL, Levy BS, Ashley SM eds, et al. CPT 2025 Professional Edition. American Medical Association. 2024. 14. New JZ Claims Modifier for Certain Medicare Part B Drugs. MM 13056. CR 13056. CMS Medicare Learning Network June 2, 2023 15. Medicare Part B Inflation Rebate Guidance: Use of the 340B Modifier. MLN Fact Sheet MLN4800856. CMS Medicare Learning Network, November 2024. 16. Professional Paper Claim Form (CMS-1500). CMS.gov. September 10, 2024. 17. CMS-1450 Medicare Uniform Institutional Provider Bill. CMS.gov. June 6, 2023. 18. Medicare Program; Contract Year 2024 Policy and Technical Changes to the Medicare Advantage Program, Medicare Prescription Drug Benefit Program, Medicare Cost Plan Program, and Programs of All-Inclusive Care for the Elderly, Federal Register April 12, 2023. <https://www.federalregister.gov/d/2023-07115/p-728> accessed June 9, 2025. 19. Medicare Advantage in 2024: enrollment Update and Key Trends. Meredith Freed, JF Biniek, A. Domico and T Neuman. KFF Aug 8th, 2024.



Rayner, the Rayner logo, OMIDRIA, the OMIDRIA logo, and OMIDRIAssure are proprietary marks of Rayner.
©2025 Rayner Group, all rights reserved. US-OM-2200073 v3 09/25



OMIDRIA®

(phenylephrine and ketorolac
intraocular solution)
1% / 0.3%

HIGHLIGHTS OF PRESCRIBING INFORMATION

These highlights do not include all the information needed to use Omidria® safely and effectively. See full prescribing information for Omidria.

Omidria® (phenylephrine and ketorolac intraocular solution) 1% / 0.3%, for addition to ocular irrigating solution
Initial U.S. Approval: 2014

INDICATIONS AND USAGE

Omidria is an alpha 1-adrenergic receptor agonist and nonselective cyclooxygenase inhibitor indicated for:

- Maintaining pupil size by preventing intraoperative miosis (1)
- Reducing postoperative pain (1)

Omidria is added to an ocular irrigating solution used during cataract surgery or intraocular lens replacement.

DOSAGE AND ADMINISTRATION

- Each vial of Omidria must be diluted prior to use for administration to a single patient undergoing cataract surgery or intraocular lens replacement.
- Dilute 4 mL of Omidria in 500 mL of ocular irrigating solution. Irrigation solution is to be used as needed for the surgical procedure. (2)

DOSAGE FORMS AND STRENGTHS

Intraocular solution containing phenylephrine 10.16 mg/mL (1%) and ketorolac 2.88 mg/mL (0.3%) for use in a single patient. (3)

CONTRAINDICATIONS

Hypersensitivity to any component of this product (4)

WARNINGS AND PRECAUTIONS

Systemic exposure to phenylephrine may cause elevations in blood pressure. (5.1)

ADVERSE REACTIONS

The most common reported adverse reactions ($\geq 2\%$) are eye irritation, posterior capsule opacification, increased intraocular pressure, and anterior chamber inflammation. (6.1)

To report SUSPECTED ADVERSE REACTIONS, contact Rayner Surgical Inc. at 1-877-OMIDRIA or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

See 17 for PATIENT COUNSELING INFORMATION

Revised: 04/2023

FULL PRESCRIBING INFORMATION: CONTENTS*

1 INDICATIONS AND USAGE

2 DOSAGE AND ADMINISTRATION

3 DOSAGE FORMS AND STRENGTHS

4 CONTRAINDICATIONS

5 WARNINGS AND PRECAUTIONS

5.1 Elevated Blood Pressure

5.2 Cross-Sensitivity or Hypersensitivity

6 ADVERSE REACTIONS

6.1 Clinical Studies Experience

8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy

8.2 Lactation

8.4 Pediatric Use

8.5 Geriatric Use

10 OVERDOSAGE

11 DESCRIPTION

12 CLINICAL PHARMACOLOGY

12.1 Mechanism of Action

12.3 Pharmacokinetics

14 CLINICAL STUDIES

16 HOW SUPPLIED/STORAGE AND HANDLING

17 PATIENT COUNSELING INFORMATION

*Sections or subsections omitted from the full prescribing information are not listed.

FULL PRESCRIBING INFORMATION:

1 INDICATIONS AND USAGE

Omidria® is added to an ocular irrigating solution used during cataract surgery or intraocular lens replacement and is indicated for maintaining pupil size by preventing intraoperative miosis and reducing postoperative ocular pain.

2 DOSAGE AND ADMINISTRATION

Omidria must be diluted prior to intraocular use. For administration to patients undergoing cataract surgery or intraocular lens replacement, 4 mL of Omidria is diluted in 500 mL of ocular irrigating solution. Irrigation solution is to be used as needed for the surgical procedure for a single patient.

The storage period for the diluted product is not more than 4 hours at room temperature or 24 hours under refrigerated conditions.

Do not use if the solution is cloudy or if it contains particulate matter.

3 DOSAGE FORMS AND STRENGTHS

Omidria is an intraocular solution containing 10.16 mg/mL (1% w/v) of phenylephrine and 2.88 mg/mL (0.3% w/v) of ketorolac for use in a single patient.

4 CONTRAINDICATIONS

Omidria is contraindicated in patients with a known hypersensitivity to any of its ingredients.

5 WARNINGS AND PRECAUTIONS

5.1 Elevated Blood Pressure

Systemic exposure to phenylephrine can cause elevations in blood pressure.

5.2 Cross-Sensitivity or Hypersensitivity

There is the potential for cross-sensitivity to acetylsalicylic acid, phenylacetic acid derivatives, and other non-steroidal anti-inflammatory drugs (NSAIDs). There have been reports of bronchospasm or exacerbation of asthma associated with the use of ketorolac in patients who either have a known hypersensitivity to aspirin/NSAIDs or a past medical history of asthma. Therefore, use Omidria with caution in individuals who have previously exhibited sensitivities to these drugs.

6 ADVERSE REACTIONS

6.1 Clinical Studies Experience

Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to the rates in the clinical studies of another drug and may not reflect the rates observed in practice.

Table 1 shows frequently reported ocular adverse reactions with an incidence of $\geq 2\%$ of adult patients as seen in the combined clinical trial results from three randomized, placebo-controlled studies [see Clinical Studies (14)].

Table 1: Ocular Adverse Reactions Reported by $\geq 2\%$ of Adult Patients

MedDRA Preferred Term	Placebo (N=462) n (%)	Omidria (N=459) n (%)
Ocular Events		
Anterior Chamber Inflammation	102 (22%)	111 (24%)
Intraocular Pressure Increased	15 (3%)	20 (4%)
Posterior Capsule Opacification	16 (4%)	18 (4%)
Eye Irritation	6 (1%)	9 (2%)
Foreign Body Sensation in Eyes	11 (2%)	8 (2%)

In a safety study that enrolled 72 pediatric patients up to 3 years old, no overall difference in safety was observed between pediatric and adult patients.

8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy

Risk Summary

There are no available data on Omidria use in pregnant women or animals to inform any drug-associated risks. Oral administration of ketorolac to rats during late gestation produced dystocia and increased pup mortality at a dose 740-times the plasma exposure at the recommended human ophthalmic dose (RHOD). Since human systemic exposure to Omidria following a lens replacement procedure is low [see Clinical Pharmacology (12.3)], the applicability of animal findings to the risk of Omidria in humans during pregnancy is unclear. Omidria should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Clinical Considerations

Fetal/Neonatal Adverse Reactions

Premature closure of the ductus arteriosus in the fetus has occurred with third trimester use of oral and injectable NSAIDs. Ketorolac plasma concentrations are detectable following ocular Omidria administration [see Clinical Pharmacology (12.3)]. The use of Omidria during late pregnancy should be avoided.

Data

Animal Data

No well-controlled animal reproduction studies have been conducted with Omidria or phenylephrine.

Ketorolac, administered during organogenesis, did not cause embryofetal abnormalities or mortalities in rabbits or rats at oral doses of 3.6 mg/kg/day and 10 mg/kg/day, respectively. These doses produced systemic exposure that is 1150 times and 4960 times the plasma exposure (based on C_{max}) at the RHOD, respectively. When administered to rats during late gestation (after Day 17 of gestation) at oral doses up to 1.5 mg/kg/day (740 times the plasma exposure at the RHOD), ketorolac produced dystocia and increased pup mortality.

8.2 Lactation

Risk Summary

There are no data on the presence of Omidria in human milk, the effects on the breastfed infant, or the effects on milk production. However, systemic exposure to Omidria, following a lens replacement procedure is low [see Clinical Pharmacology (12.3)]. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for Omidria and any potential adverse effects on the breastfed child from Omidria.

8.4 Pediatric Use

The safety and effectiveness of Omidria have been established in the pediatric population from neonates to adolescents (birth to younger than 17 years). Use of Omidria in this population is supported by evidence from adequate and well-controlled studies of Omidria in adults with additional data from a single active-controlled safety study in pediatric patients up to 3 years old [see *Clinical Studies* (14)].

No overall differences in safety were observed between pediatric and adult patients.

8.5 Geriatric Use

No overall differences in safety or effectiveness have been observed between elderly and adult patients.

10 OVERDOSAGE

Systemic overdosage of phenylephrine may cause a rise in blood pressure. It may also cause headache, anxiety, nausea, vomiting, and ventricular arrhythmias. Supportive care is recommended.

11 DESCRIPTION

Omidria is a sterile aqueous solution, containing the α_1 -adrenergic receptor agonist phenylephrine HCl and the nonsteroidal anti-inflammatory ketorolac tromethamine, for addition to ocular irrigating solution.

The descriptions and structural formulae are:

Phenylephrine Hydrochloride Drug Substance:


Common Name: phenylephrine hydrochloride

Chemical Name: (-)-m-Hydroxy- α -[(methylamino)methyl]benzyl alcohol hydrochloride

Molecular Formula: $C_9H_{13}NO_2 \cdot HCl$

Molecular Weight: 203.67 g/mole

Figure 1: Chemical Structure for Phenylephrine HCl



Ketorolac Tromethamine Drug Substance:


Common Name: ketorolac tromethamine

Chemical Name: ($\pm$)-5-Benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid; 2-amino-2-(hydroxymethyl)-1,3-propanediol (1:1)

Molecular Formula: $C_{15}H_{13}NO_3 \cdot C_4H_{11}NO_3$

Molecular Weight: 376.40 g/mole

Figure 2: Chemical Structure for Ketorolac Tromethamine



Omidria is a clear, colorless to slightly yellow, sterile solution concentrate with a pH of approximately 6.3.

Each vial of Omidria contains:

Actives: phenylephrine hydrochloride 12.4 mg/mL equivalent to 10.16 mg/mL of phenylephrine and ketorolac tromethamine 4.24 mg/mL equivalent to 2.88 mg/mL of ketorolac.

Inactives: citric acid monohydrate; sodium citrate dihydrate; water for injection; may include sodium hydroxide and/or hydrochloric acid for pH adjustment.

12 CLINICAL PHARMACOLOGY

12.1 Mechanism of Action

The two active pharmaceutical ingredients (API) in Omidria, phenylephrine and ketorolac, act to maintain pupil size by preventing intraoperative miosis, and reducing postoperative pain.

Phenylephrine is an α_1 -adrenergic receptor agonist and, in the eye, acts as a mydriatic agent by contracting the radial muscle of the iris. Ketorolac is a nonsteroidal anti-inflammatory that inhibits both cyclooxygenase enzymes (COX-1 and COX-2), resulting in a decrease in tissue concentrations of prostaglandins to reduce pain due to surgical trauma. Ketorolac, by inhibiting prostaglandin synthesis secondary to ocular surgical insult or direct mechanical stimulation of the iris, also prevents surgically induced miosis.

12.3 Pharmacokinetics

In a pharmacokinetic study evaluating Omidria, systemic exposure to both phenylephrine and ketorolac was low or undetectable.

A single-dose of Omidria as part of the irrigation solution was administered in 14 patients during lens replacement surgery. The volume of irrigation solution used during surgery ranged between 150 mL to 300 mL (median 212.5 mL). Detectable phenylephrine plasma concentrations were observed in one of 14 patients (range 1.2 to 1.4 ng/mL) during the first 2 hours after the initiation of Omidria administration. The observed phenylephrine plasma concentrations could not be distinguished from the preoperative administration of phenylephrine 2.5% ophthalmic solution prior to exposure to Omidria.

Ketorolac plasma concentrations were detected in 10 of 14 patients (range 1.0 to 4.2 ng/mL) during the first 8 hours after the initiation of Omidria administration. The maximum ketorolac concentration was 15 ng/mL at 24 hours after the initiation of Omidria administration, which may have been due to application of postoperative ketorolac ophthalmic solution.

14 CLINICAL STUDIES


Studies in Adults

The efficacy and safety of Omidria were evaluated in two Phase 3, randomized, multicenter, double-masked, placebo-controlled clinical trials in 808 adult patients undergoing cataract surgery or intraocular lens replacement.

Patients were randomized to either Omidria or placebo. Patients were treated with preoperative topical mydriatic and anesthetic agents. Pupil diameter was measured throughout the surgical procedure. Postoperative pain was evaluated by self-administered 0-100 mm visual analog scales (VAS).

Mydriasis was maintained in the Omidria-treated groups while the placebo-treated groups experienced progressive constriction.


Figure 3: Intraoperative Pupil Diameter (mm) Change-from-Baseline



At the end of cortical clean-up, 23% of placebo-treated patients and 4% of Omidria-treated patients had a pupil diameter less than 6 mm ($p < 0.01$).

Pain during the initial 10-12 hours postoperatively was statistically significantly less in the Omidria-treated groups than in the placebo-treated groups.

Figure 4: Postoperative Mean Visual Analog Scale (VAS) Scores for Pain



During the 10-12 hours postoperatively, 26% of Omidria-treated patients reported no pain (VAS = 0 at all timepoints) while 17% of placebo-treated patients reported no pain ($p < 0.01$).

Study in Pediatric Patients

The safety of Omidria was evaluated in a single, randomized, multicenter, double-masked, active-controlled clinical study in 72 pediatric patients up to 3 years old undergoing cataract surgery with or without intraocular lens replacement.

Patients were randomized to either Omidria or phenylephrine. Patients were treated with preoperative topical mydriatic and anesthetic agents. As in the adult studies, mydriasis was maintained in the Omidria-treated group. No overall differences in safety were observed between pediatric and adult patients.

16 HOW SUPPLIED/STORAGE AND HANDLING

Omidria (phenylephrine and ketorolac intraocular solution) 1%/0.3% is supplied in a clear, 5-mL glass, single-patient-use vial containing 4 mL of sterile solution, for addition to ocular irrigating solution.

Omidria is supplied in a multi-pack containing:

4 vials: NDC 82604-600-04 or

10 vials: NDC 82604-600-10

Storage: Store at 20° to 25°C (68° to 77°F). Protect from light.

17 PATIENT COUNSELING INFORMATION

Inform patients that they may experience sensitivity to light.

Rayner Surgical Inc.

Suite 102, 14335 NE 24th Street

Bellevue, WA 98007

Patented product see

www.rayner.com/patents

for further details.

© Rayner 2023

OMIDRIA® and the OMIDRIA® logo are registered trademarks of Rayner Surgical Inc.

640069

Revised: 04/2023

US-OM-2300042 04/23